On October 16, 2024 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place October 19-23 in Hamburg, Germany (Press release, Bicycle Therapeutics, OCT 16, 2024, View Source [SID1234647240]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The German Cancer Consortium (DKTK), part of a cooperative network with the German Cancer Research Center (DKFZ), will present the first human imaging data for a BRC targeting MT1-MMP, a tumor antigen overexpressed in many cancers, during an oral presentation. In an online-only poster (e-poster), the company will present information about BRCs for radioisotope delivery to solid tumors. Additionally, Bicycle Therapeutics will host a conference call and webcast for analysts and investors on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline the company’s radiopharmaceuticals strategy.
Oral Presentation by DKTK:
Title: Preclinical characterization of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic applications
Session Number: 1504
Session Title: M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Targeted Radionuclide Therapy
Date and Time: Tuesday, Oct. 22, at 3:50-4 p.m. CEST
Presentation Number: OP-673
Presenter: Ann-Christin Eder, Ph.D., University Medical Center Freiburg
E-Poster by Bicycle Therapeutics:
Title: Bicycle Radionuclide Conjugates for radioisotope delivery to solid tumors
Session Number: EP-03
Session Title: Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology
e-Poster Number: EP-0032
Lead Author: Gemma Mudd, Ph.D., Bicycle Therapeutics
Conference Call and Webcast Information
Bicycle Therapeutics will host a conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the first human imaging data and outline the company’s radiopharmaceuticals strategy. To access the call, please dial +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and ask to join the Bicycle Therapeutics call. A live webcast and replay of the conference call will be available in the Investor section of the company’s website, www.bicycletherapeutics.com.